1685P Is cancer what determines COVID-19 oncological patient’s outcome or are other external factors involved? Experience in a hospital in Madrid, Spain

Background: There are no large reported series determining the outcome of cancer patients with COVID-19 We aimed to determine whether differences exist in COVID-19 related mortality between cancer patients and the general population in our hospital, and we also describe associated risk factors Methods: We reviewed 2216 medical records of all patients admitted to hospital with COVID-19 diagnosis between 5 March and 13 May 2020 Study data were collected using REDCap electronic data capture tools We described COVID-19 cumulative incidence in cancer patients, treatment outcome, mortality and associated risk factors Results: We detected 85/2216 cancer patients in all COVID-19 diagnoses Mortality rate: 40/85 cancer patients vs 260/2131 patients in the general ward (P<0 001) Median age: 76 years old (34-94), 50/85 male patients Most frequent histologies: lung cancer (22/85), colorectal cancer (19/85) and prostate cancer (15/85) Most frequent staging: metastatic disease (32/85) Only 2/85 patients were admitted to ICU Mortality was associated with older median age (79 5 vs 73, P=0 03), high d dimer levels (1630 vs 830, P=0 03), high LDH levels (315 5 vs 224, P=0 003), bilateral pneumonia (24/42 vs 5/22 with unilateral pneumonia, P=0 02), acute respiratory distress syndrome (ARDS) (12/13 vs 28/72 without ARDS, P<0 0001) and metastatic disease (20/32 metastatic vs 20/53 non-metastatic, P=0 02) Differences were maintained in multivariate analyses regarding ARDS (OR 23 7, P=0 007) and metastatic disease (OR 2 5, P=0 05) Combined treatment with hydroxychloroquine and azithromycin showed a better outcome in uni and multivariate analyses with only 21/61 dead patients (OR 0 13, P=0 005), adjusted by sex, histology, staging, ARDS and comorbidities Conclusions: COVID-19 had significant mortality in cancer patients High D dimer and LDH levels and ARDS development in elderly metastatic patients carry an elevated risk of death in cancer patients diagnosed with COVID-19 However, only 2/85 patients were admitted to ICU and this data was decisive Combined hydroxychloroquine and azithromycin could be a good treatment option in COVID-19 cancer patients It is a priority to create measures to avoid COVID-19 transmission in oncological patients Legal entity responsible for the study: Medical Oncology Department, HU Infanta Leonor Funding: Has not received any funding Disclosure: All authors have declared no conflicts of interest